FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249187107> ?p ?o ?g. }

• W4249187107 abstract "Although the benefits of recombinant human erythropoietin (rHu EPO) administration in dialysis patients have been demonstrated the optimal frequency regimen has not as yet been established. Treatment with rHu EPO is expensive, there is therefore a need for optimising the efficiency of its administration.The objectives of this review were to assess the effects of different frequency regimens of rHu EPO administration in dialysis patients in terms of i) effectiveness (correction of anaemia, quality of life and freedom from adverse events) ii) efficiency (optimal resource use) of different rHu EPO dose regimen policies.We searched MEDLINE (1980 to May Week 3 2001), EMBASE (1984 to Week 24 2001), BIOSIS (1985 to January 1997), CINAHL (1982 to October 1997), The Cochrane Library (Issue 1, 1997), CHEMABS (1984 to November 1996), SIGLE (1980 to June 1996), CRIB (10th edition, 1995), UK NRR (14th consolidation, September 1996), RSC ( 1980 to February 1997), HealthSTAR (1995 to October 1997), IBSS (1984 to July 1997), NEED (July 1997) and reference lists of relevant articles. We contacted biomedical companies and investigators in the field and we hand searched Kidney International (including all supplements but excluding all conference proceedings except for 1994) July 1983 to May 1997 inclusive. The Internet was also searched on: August 1997. We had also identified some studies from a previous broad search for all randomised controlled trials (RCTs) relevant to the management of end-stage renal disease. Date of the most recent search: June 2001.All randomised or quasi randomised controlled trials comparing different frequencies of rHu EPO administration in dialysis patients. Subgroup analyses were performed comparing haemodialysis and CAPD patients and also subcutaneous and intravenous administration.Only published data were used. Data were abstracted by a single investigator on to a standard form. The data abstracted were relevant to the predetermined outcome measures: measures of correction of anaemia, rHu EPO dose, quality of life measures, adverse events, number of withdrawals from study, mortality. Where appropriate, a summary relative risk (RR) was calculated for dichotomous data and a weighted mean difference (WMD) or standardised mean difference (SMD) for continuous data.Eight studies met our inclusion criteria. When once a week administration was compared with twice weekly there was no significant difference in the ability to maintain the target haemoglobin (RR 1.00, 95% CI 0.42 to 2.40). Mean haemoglobin after twelve weeks of therapy was not different between the two groups (WMD -0.21g/dl, 95% CI -0.98 to 0.56). No difference was found in mean haemoglobin or haematocrit at the end of any studies which compared once with thrice weekly administration of rHu EPO (SMD -0.31, 95% CI -0.67 to 0.06). A single study which compared once with more that thrice weekly administration showed no significant difference in mean haemoglobin at the end of the maintenance phase (mean difference -0.2g/dl, 95% CI -0.65 to 0.25). The dosage of erythropoietin required by those on haemodialysis receiving rHu EPO once weekly was just significantly more (WMD 12.0 U/kg, 95% CI 0.24 to 23.76) than those receiving it twice weekly but the confidence interval is wide. No such difference was found for CAPD patients nor when the results were combined (WMD 5.15 U/kg, 95% CI -3.74 to 14.05). The result was not significant when comparing once weekly with thrice weekly administration (WMD 10.00 U/kg, 95% CI -80.87 to 100.87). There was no difference in the frequency of adverse events between any of the groups studies.There is no significant difference between once weekly versus thrice weekly subcutaneous administration of rHu EPO. Once weekly administration of rHu EPO would require an additional 12U/kg/week for patients on haemodialysis, however this is based on one very small study. The cost of this additional hRu EPO nee, however this is based on one very small study. The cost of this additional hRu EPO needs to assessed, in particular with regard to patient preference and compliance." @default.
• W4249187107 created "2022-05-12" @default.
• W4249187107 creator A5000940073 @default.
• W4249187107 creator A5030747328 @default.
• W4249187107 creator A5032035046 @default.
• W4249187107 creator A5045206654 @default.
• W4249187107 creator A5053975934 @default.
• W4249187107 creator A5060405872 @default.
• W4249187107 creator A5060525155 @default.
• W4249187107 creator A5081249667 @default.
• W4249187107 creator A5085130210 @default.
• W4249187107 date "2002-04-22" @default.
• W4249187107 modified "2023-10-14" @default.
• W4249187107 title "Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients" @default.
• W4249187107 cites W1970783249 @default.
• W4249187107 cites W1983569135 @default.
• W4249187107 cites W2010455909 @default.
• W4249187107 cites W2018618415 @default.
• W4249187107 cites W2019289959 @default.
• W4249187107 cites W2027433361 @default.
• W4249187107 cites W2029738096 @default.
• W4249187107 cites W2046607168 @default.
• W4249187107 cites W2059364207 @default.
• W4249187107 cites W2067796977 @default.
• W4249187107 cites W2112657209 @default.
• W4249187107 cites W2138371695 @default.
• W4249187107 cites W2164800907 @default.
• W4249187107 cites W2184460805 @default.
• W4249187107 cites W2315613377 @default.
• W4249187107 cites W2321111200 @default.
• W4249187107 cites W4213306416 @default.
• W4249187107 doi "https://doi.org/10.1002/14651858.cd003895" @default.
• W4249187107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12519614" @default.
• W4249187107 hasPublicationYear "2002" @default.
• W4249187107 type Work @default.
• W4249187107 citedByCount "7" @default.
• W4249187107 countsByYear W42491871072014 @default.
• W4249187107 crossrefType "reference-entry" @default.
• W4249187107 hasAuthorship W4249187107A5000940073 @default.
• W4249187107 hasAuthorship W4249187107A5030747328 @default.
• W4249187107 hasAuthorship W4249187107A5032035046 @default.
• W4249187107 hasAuthorship W4249187107A5045206654 @default.
• W4249187107 hasAuthorship W4249187107A5053975934 @default.
• W4249187107 hasAuthorship W4249187107A5060405872 @default.
• W4249187107 hasAuthorship W4249187107A5060525155 @default.
• W4249187107 hasAuthorship W4249187107A5081249667 @default.
• W4249187107 hasAuthorship W4249187107A5085130210 @default.
• W4249187107 hasConcept C126322002 @default.
• W4249187107 hasConcept C141071460 @default.
• W4249187107 hasConcept C168563851 @default.
• W4249187107 hasConcept C177713679 @default.
• W4249187107 hasConcept C197934379 @default.
• W4249187107 hasConcept C2776478404 @default.
• W4249187107 hasConcept C2779134260 @default.
• W4249187107 hasConcept C2779978075 @default.
• W4249187107 hasConcept C2781413609 @default.
• W4249187107 hasConcept C3019040382 @default.
• W4249187107 hasConcept C71924100 @default.
• W4249187107 hasConcept C95190672 @default.
• W4249187107 hasConceptScore W4249187107C126322002 @default.
• W4249187107 hasConceptScore W4249187107C141071460 @default.
• W4249187107 hasConceptScore W4249187107C168563851 @default.
• W4249187107 hasConceptScore W4249187107C177713679 @default.
• W4249187107 hasConceptScore W4249187107C197934379 @default.
• W4249187107 hasConceptScore W4249187107C2776478404 @default.
• W4249187107 hasConceptScore W4249187107C2779134260 @default.
• W4249187107 hasConceptScore W4249187107C2779978075 @default.
• W4249187107 hasConceptScore W4249187107C2781413609 @default.
• W4249187107 hasConceptScore W4249187107C3019040382 @default.
• W4249187107 hasConceptScore W4249187107C71924100 @default.
• W4249187107 hasConceptScore W4249187107C95190672 @default.
• W4249187107 hasLocation W42491871071 @default.
• W4249187107 hasLocation W42491871072 @default.
• W4249187107 hasOpenAccess W4249187107 @default.
• W4249187107 hasPrimaryLocation W42491871071 @default.
• W4249187107 hasRelatedWork W2381982637 @default.
• W4249187107 hasRelatedWork W2393508812 @default.
• W4249187107 hasRelatedWork W2914141471 @default.
• W4249187107 hasRelatedWork W3013041320 @default.
• W4249187107 hasRelatedWork W3029323012 @default.
• W4249187107 hasRelatedWork W3096683796 @default.
• W4249187107 hasRelatedWork W3132173363 @default.
• W4249187107 hasRelatedWork W3184425712 @default.
• W4249187107 hasRelatedWork W4293280734 @default.
• W4249187107 hasRelatedWork W4360608871 @default.
• W4249187107 isParatext "false" @default.
• W4249187107 isRetracted "false" @default.
• W4249187107 workType "reference-entry" @default.